nature portfolio

Corresponding author(s):	Chaplin-Kramer
Last updated by author(s):	Oct 3, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

~ .			
∨ t	· 2†	ist	$1 \cap C$

Statistics				
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed				
\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description of all covariates tested				
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code				
Policy information about <u>availability of computer code</u>				
Data collection We used InVEST version 3.8 (free and open-source, available at naturalcapitalproject.stanford.edu/software/invest) and Co\$tingNature version 3 (free for non-commercial uses, available at www.policysupport.org/costingnature), along with several open-source pre-published datasets.				
Data analysis We used prioritizr available at https://prioritizr.net/				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				
Data				
Policy information about <u>availability of data</u>				
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:				

- For clinical datasets or third party data, please ensure that the statement adheres to our policy

- Accession codes, unique identifiers, or web links for publicly available datasets

- A description of any restrictions on data availability

Field-specific reporting				
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
Life sciences	Behavioural & social sciences			
For a reference copy of the docume	ent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Ecological, evolutionary & environmental sciences study design				
All studies must disclose on	these points even when the disclosure is negative.			
Study description	We ran spatially explicit models of nature's contributions to people and integrated their outputs along with pre-existing datasets into a multi-objective optimization.			
Research sample	Spatially-explicit GIS data			
Sampling strategy	Data were resampled from 300 m resolution to 2 km resolution to include in the spatial optimization; otherwise no sub-sampling was performed.			
Data collection	Data were provided by coauthors Chaplin-Kramer, Sharp, Mulligan, McIntyre, Spalding, Watson, Keys, and Roehrdanz. Methods to produce each spatial dataset are detailed in the Supplementary Information			
Timing and spatial scale	Data are mostly from 2015, but span the 2000-2017 window (annual/snapshot), and are global in extent.			
Data exclusions	No data were excluded			
Reproducibility	Code is published to allow reproducibility			
Randomization	Randomization is not necessary because all data are included in the optimization			
Blinding	Blinding is not relevant because all data are included in the optimization			
Did the study involve field	d work? Yes No			
Reporting for specific materials, systems and methods				
	enthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, evant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experime				
n/a Involved in the study				
Antibodies Substitute and lines	ChIP-seq			
Eukaryotic cell lines Palaeontology and a	Flow cytometry MRI-based neuroimaging			
Animals and other o				
Human research participants				
Clinical data				
Dual use research o	f concern			